CFRX

ContraFect Corporation [CFRX] Stock Forecast

Q: What is ContraFect Corporation stock symbol ?

ContraFect Corporation is a US stock, located in Yonkers of Ny and trading under the symbol CFRX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

CFRX Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

Does not have any significance market cap ($2.7M)

CFRX has less than 1 year of cash runway

Top 10 Correlated ETFs

CFRX

Top 10 Correlated Stocks

CFRX

In the News

06:00 26 Mar 2023 CFRX

Penny Stock Investing for Passive Income: Opportunities and Risks

Use these tips for making passive income with penny stocks The post Penny Stock Investing for Passive Income: Opportunities and Risks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

08:27 26 Mar 2023 CFRX

Why Is ContraFect (CFRX) Stock Up 20% Today?

ContraFect (NASDAQ: CFRX ) stock is rising higher on Tuesday as investors await news about its potential delisting from the Nasdaq Capital Market. ContraFect last updated investors on Friday about its delisting situation.

08:38 26 Mar 2023 CFRX

Why Is ContraFect (CFRX) Stock Down 23% Today?

ContraFect (NASDAQ: CFRX ) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market. ContraFect notes in a filing with the SEC that the Nasdaq staff has rejected its request for continued listing on the exchange.

09:21 26 Mar 2023 CFRX

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

11:10 26 Mar 2023 CFRX

Why Is ContraFect (CFRX) Stock Down 80% Today?

A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging. The post Why Is ContraFect (CFRX) Stock Down 80% Today?

10:18 26 Mar 2023 CFRX

Penny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675%

Penny stocks to buy according to analysts. The post Penny Stocks To Buy Today?

02:30 26 Mar 2023 CFRX

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.

07:30 26 Mar 2023 CFRX

ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022

YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to present two posters at the ASM Microbe Conference to be held in Washington, D.C. from June 9-13, 2022. The data being presented features the Company's Breakthrough Therapy designated product candidate, exebacase, currently being studied in a pivotal Phase 3 superiority design trial.

08:30 26 Mar 2023 CFRX

ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference

YONKERS, N.Y., March 21, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference, which is being held virtually from March 28–30, 2022. The live fireside chat will be with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group on Monday, March 28, 2022 at 2:00pm ET.

07:30 26 Mar 2023 CFRX

ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference

YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference, which is being held virtually from February 14–18, 2022. The fireside chat will be held on Thursday, February 17, 2022 at 10:00 AM ET.

CFRX Financial details

Company Rating

Neutral

Market Cap

2.7M

Income

-75.6M

Revenue

Book val./share

-6.31

Cash/share

35.89

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

22 Mar 2023

P/E

-0.01

Forward P/E

PEG

-0

P/S

P/B

-0.33

P/C

0.06

P/FCF

-0.12

Quick Ratio

0.74

Current Ratio

0.84

Debt / Equity

-8.42

LT Debt / Equity

-0.75

EPS (TTM)

-153.75

EPS next Y

EPS next Q

EPS this Y

-27.96%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-5.65%

SMA20

-47.78%

SMA50

-75.46%

SMA100

-85.14%

Inst Own

28.74%

Inst Trans

6.19%

ROA

-328%

ROE

-339%

ROC

96.11%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

1.3M

Shs Float

479.06K

Target Price

52W Range

1.75-363.2

52W High

-99.43%

52W Low

+108%

RSI

35.06

Rel Volume

0.18

Avg Volume

667.57K

Volume

121.61K

Perf Week

-0.48%

Perf Month

-58.4%

Perf Quarter

-84.52%

Perf Half Y

-87.23%

Beta

0.492458

Volatility

0.09%, 1.02%

Prev Close

8.33%

Price

2.08

Change

6.95%

CFRX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	0	0	0	0	0
Net income per share	-223.29	-396.35	-123.57	-98.95	-71.28
Operating cash flow per share	-352.96	-276.18	-264.89	-116.63	-144.53
Free cash flow per share	-352.96	-277.59	-265.08	-116.63	-144.53
Cash per share	674.21	320.29	233.56	149.33	190.78
Book value per share	448.86	58.29	150.13	44.35	173.53
Tangible book value per share	448.86	58.29	150.13	44.35	173.53
Share holders equity per share	448.86	58.29	150.13	44.35	173.53
Interest debt per share	0	0	6.1	2.27	11.48
Market cap	56.15M	116.38M	51.42M	114.96M	59.87M
Enterprise value	49.16M	108.06M	31.13M	100.12M	46.48M
P/E ratio	-3.62	-3.09	-4.02	-4.08	-2.95
Price to sales ratio	0	0	0	0	0
POCF ratio	-2.29	-4.43	-1.87	-3.46	-1.46
PFCF ratio	-2.29	-4.41	-1.87	-3.46	-1.46
P/B Ratio	1.8	21	3.31	9.11	1.21
PTB ratio	1.8	21	3.31	9.11	1.21
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-3.21	-2.88	-2.47	-3.58	-2.31
EV to operating cash flow	-2	-4.12	-1.13	-3.02	-1.13
EV to free cash flow	-2	-4.09	-1.13	-3.02	-1.13
Earnings yield	-0.28	-0.32	-0.25	-0.24	-0.34
Free cash flow yield	-0.44	-0.23	-0.53	-0.29	-0.69
Debt to equity	0.61	4.93	1.25	3.05	0.35
Debt to assets	0.38	0.83	0.56	0.75	0.26
Net debt to EBITDA	0.46	0.22	1.61	0.53	0.66
Current ratio	11.02	5.42	3.06	7.8	5.16
Interest coverage	0	0	0	0	0
Income quality	1.58	0.7	2.14	1.18	2.03
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0.01	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	-0.88	-0.12	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	1.5K	720.98	646.06	314.23	527.54
ROIC	-0.76	-2.1	1.74	-1.87	-1.52
Return on tangible assets	-0.31	-1.15	-0.37	-0.55	-0.3
Graham Net	400.86	32.83	45.59	14.04	129.68
Working capital	44.28M	25.64M	20.7M	41.23M	50.69M
Tangible asset value	31.19M	5.54M	15.54M	12.62M	49.38M
Net current asset value	29.71M	4.11M	11.3M	8.79M	45.48M
Invested capital	0	0	0.04	0.05	0.07
Average receivables	0	0	0	0	0
Average payables	1.43M	1.36M	2.02M	2.21M	2.1M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.5	-6.8	-0.82	-2.23	-0.41
Capex per share	0	-1.4	-0.19	0	0

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-09-30	2021-12-31	2022-03-31	2022-06-30	2022-09-30
Revenue per share	0	0	0	0	0
Net income per share	0	-41.25	-41	-36.79	-34.71
Operating cash flow per share	-66.22	26.31	-23.93	-29.66	-19.64
Free cash flow per share	-66.22	26.31	-23.93	-29.66	-19.67
Cash per share	0	110.41	86	55.53	35.89
Book value per share	107.81	100.43	61.01	26.21	-6.31
Tangible book value per share	107.81	100.43	61.01	26.21	-6.31
Share holders equity per share	107.81	100.43	61.01	26.21	-6.31
Interest debt per share	8.15	6.64	6.46	6.26	6.08
Market cap	159.3M	103.45M	143.56M	120.75M	6.61M
Enterprise value	163.31M	90.06M	137.1M	114.28M	4.92M
P/E ratio	0	-1.28	-1.78	-1.67	-0.1
Price to sales ratio	0	0	0	0	0
POCF ratio	-4.89	8	-12.2	-8.28	-0.68
PFCF ratio	-4.89	8	-12.2	-8.28	-0.68
P/B Ratio	3.01	2.1	4.79	9.37	-2.13
PTB ratio	3.01	2.1	4.79	9.37	-2.13
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-14.11	-4.43	-6.81	-6.51	-0.29
EV to operating cash flow	-5.02	6.96	-11.65	-7.84	-0.51
EV to free cash flow	-5.02	6.96	-11.65	-7.84	-0.51
Earnings yield	0	-0.2	-0.14	-0.15	-2.58
Free cash flow yield	-0.2	0.13	-0.08	-0.12	-1.46
Debt to equity	0.47	0.35	0.87	2.17	-8.42
Debt to assets	0.32	0.26	0.46	0.68	1.13
Net debt to EBITDA	-0.35	0.66	0.32	0.37	0.1
Current ratio	7.48	5.16	3.16	1.83	0.84
Interest coverage	0	0	0	0	-2.43K
Income quality	0	-0.64	0.58	0.81	0.57
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	0	305.31	237.24	147.29	70.21
ROIC	0	-0.45	-0.56	-1.92	13.34
Return on tangible assets	0	-0.3	-0.36	-0.44	-0.74
Graham Net	-50.52	75.05	33.03	-1.24	-17.27
Working capital	64M	50.69M	35.71M	17.11M	-3.73M
Tangible asset value	53.01M	49.38M	30M	12.89M	-3.1M
Net current asset value	49.04M	45.48M	26.23M	9.8M	-6.09M
Invested capital	0.08	0.07	0.11	0.24	-0.96
Average receivables	0	0	0	0	0
Average payables	3.01M	2.68M	5.33M	9.77M	13.31M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0	-0.41	-0.67	-1.4	5.5
Capex per share	0	0	0	0	0

CFRX Frequently Asked Questions

What is ContraFect Corporation stock symbol ?

ContraFect Corporation is a US stock , located in Yonkers of Ny and trading under the symbol CFRX

What is ContraFect Corporation stock quote today ?

ContraFect Corporation stock price is $2.08 today.

Is ContraFect Corporation stock public?

Yes, ContraFect Corporation is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 667.57K
Market Capitalization 2.7M
Employee 38
CEO Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.
Headquarters Yonkers,NY,US
IPO Date 2014-07-29
Website https://www.contrafect.com

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.